The efficacy and safety of 1064nm picosecond laser combined with IPL in the treatment of post acne atrophic scar

1064nm picosecond laser combined with IPL and IPL alone in the treatment of post acne atrophic scar: a randomised, split-face clinical trail

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026565

Enrollment

Unknown

Registered

2019-10-14

Start date

2019-10-31

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post acne atrophic scar

Interventions

experimental group:fractionated 1064nm picosecond laser combined with IPL treatment

control group:IPL treatment alone

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Patients with post acne atrophic scar aged 18-60, with ECCA >= 20 and post inflammatory erythema; 2) Scaring has persisted for more than 1 year and has similar distribution and servirity for both sides; 3) Compliable to treatment regimen, assessment and follow-up requirements.

Exclusion criteria

Exclusion criteria: 1)Patients with light therapy, chemical peeling or filler therapy within 1 year; 2)Smokers; 3)Patients with scar diathesis or malhealing history or active skin diseases that are prone to koebner phenomenon; 4)Patients with facial skin conditions that can be severed by light, facial skin cancer history or virus infection history; 5)Patients with recent history of photosensitive drug use such as systemic retinoids treatment within 3 months, minocyclin or quinolone treatment within 1 month; 6)Patients with recent facial pigmentation history by light exposure; 7)Patients in pregnancy or lactation; 8)Patients with major health issues such as diabetes, epilepsy, heart failure, respiratory failure, impaired renal or liver function(impaired liver or renal function is defined ALT>2 fold of upper limit or Cr>2 fold of upper limit); 9)Patients with mental illness history; 10)Patients who currently participating other clinical trials; 11)Other conditions judged by the investigator to be unfavorable to the patients or the research.

Design outcomes

Secondary

Measure	Time frame
patient global improvment;dermatologic quality of life;patient satisfaction;	—

Primary

Measure	Time frame
ECCA grading scale;atrophic scar lesion count;clinician improvment assessment;	—

Countries

China

Contacts

Public ContactYan Shuxian

Department of Dermatology, Huashan Hospital, Fudan University

shuxianyan0225@126.com+86 13817200326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026